Cargando…

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

BACKGROUND: To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile, in addition to pelvic radiotherapy, for women with high risk and advanced stage endometrial cancer. METHODS: Eighty-three participants in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blinman, Prunella, Mileshkin, Linda, Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie, O'Connell, Rachel, Creutzberg, Carien L, Stockler, Martin R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104894/ https://www.ncbi.nlm.nih.gov/pubmed/27764842 http://dx.doi.org/10.1038/bjc.2016.323

Ejemplares similares

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
por: Vermij, Lisa, et al.
Publicado: (2020)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2018)

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2019)

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
por: de Boer, S M, et al.
Publicado: (2018)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
por: Obermair, Andreas, et al.
Publicado: (2021)

Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
por: Farrell, Rhonda, et al.
Publicado: (2021)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

Ultrasound guided conformal brachytherapy of cervix cancer: survival, patterns of failure, and late complications
por: Narayan, Kailash, et al.
Publicado: (2014)

We should not settle for low-level evidence but should always use the best available evidence
por: Narayan, Kailash, et al.
Publicado: (2014)

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
por: Emons, Günther, et al.
Publicado: (2018)

Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
por: Teng, Christina, et al.
Publicado: (2022)

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
por: Kok, Peey-Sei, et al.
Publicado: (2019)

Distinguishing Intergroup and Long-Distance Relationships
por: Pisor, Anne C., et al.
Publicado: (2022)

Getting connected: Intergroup contact on Facebook
por: Schwab, Anne Katrin, et al.
Publicado: (2018)

Scanxiety Conversations on Twitter: Observational Study
por: Bui, Kim Tam, et al.
Publicado: (2023)

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
por: Bagnoli, Marina, et al.
Publicado: (2019)

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
por: Blinman, Prunella, et al.
Publicado: (2020)

How Can Intergroup Interaction Be Bad If Intergroup Contact Is Good? Exploring and Reconciling an Apparent Paradox in the Science of Intergroup Relations
por: MacInnis, Cara C., et al.
Publicado: (2015)

A Network Analysis of the Association Between Intergroup Contact and Intergroup Relations
por: Yu, Dongfang, et al.
Publicado: (2022)

Scanxiety: a scoping review about scan-associated anxiety
por: Bui, Kim Tam, et al.
Publicado: (2021)

The evolution of intergroup cooperation
por: Rodrigues, António M. M., et al.
Publicado: (2023)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

Intergroup contact in multiple adolescents’ contexts: The Intergroup Contact Interactions Scale (ICIS)
por: Karataş, Savaş, et al.
Publicado: (2023)

(Bad) Feelings about Meeting Them? Episodic and Chronic Intergroup Emotions Associated with Positive and Negative Intergroup Contact As Predictors of Intergroup Behavior
por: Kauff, Mathias, et al.
Publicado: (2017)

How long is too long? A scoping review of health system delays in lung cancer
por: Malalasekera, Ashanya, et al.
Publicado: (2018)

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
por: Lee, Yeh Chen, et al.
Publicado: (2022)

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
por: Lawrence, Nicola J., et al.
Publicado: (2018)

ENhAncing Lifestyle Behaviors in EndometriaL CancEr (ENABLE): A Pilot Randomized Controlled Trial
por: Edbrooke, Lara, et al.
Publicado: (2022)

Intergroup contact and team functioning among nursing students: the mediation role of intergroup anxiety
por: Marletta, Giuseppe, et al.
Publicado: (2017)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Affective Dimensions of Intergroup Humiliation
por: Leidner, Bernhard, et al.
Publicado: (2012)

The neuroscience of intergroup threat and violence
por: Lantos, Dorottya, et al.
Publicado: (2021)

Ostracism and sharing in an intergroup context
por: Reem, Hila, et al.
Publicado: (2023)

Steeling Ourselves: Intragroup Communication while Anticipating Intergroup Contact Evokes Defensive Intergroup Perceptions
por: Greijdanus, Hedy, et al.
Publicado: (2015)

Intergroup Reconciliation between Flemings and Walloons: The Predictive Value of Cognitive Style, Authoritarian Ideology, and Intergroup Emotions
por: Van Assche, Jasper, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ikr4f76eqolv3p99t1gcv68ugh